title: Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density.
abstract: OBJECTIVE
  To determine the effect of methotrexate (MTX) on bone mineral density (BMD) in rheumatoid arthritis (RA).
  
  
  METHODS
  One hundred and sixteen non-steroid-treated RA subjects (90 women) were studied in a prospective, longitudinal, non-randomized study. Subjects started MTX (n=36) or sulphasalazine (n=23) or continued long-term (>5 yr) treatment with MTX (n=28) or other disease-modifying anti-rheumatic drugs (n=29). BMD was estimated at entry and after 1 yr. Markers of bone turnover were measured at entry and at 1 yr, and additionally at 3 and 6 months in those starting treatment. Bone biopsies were taken before and after MTX treatment in four subjects. The primary outcome was change in BMD Z score and secondary outcomes were changes in bone turnover markers and bone formation by histomorphometry.
  
  
  RESULTS
  Univariate analysis of covariance found that MTX at baseline was associated with reduced BMD at the femoral neck. However, femoral neck BMD was also associated with radiological damage score for the hand. Multivariate analysis and discriminant analysis of the subset of post-menopausal women showed that reduced bone density associated with MTX was due to confounders such as disease activity. There was no adverse effect of MTX on bone turnover markers or on measures of bone formation in biopsies.
  
  
  CONCLUSIONS
  No adverse effect of low-dose MTX (mean 10 mg/week) on bone formation in RA was found.
authors.affiliation: The Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK.
authors.forename: N J
authors.initials: NJ
authors.lastname: Minaur
authors.forename: D
authors.initials: D
authors.lastname: Kounali
authors.forename: S
authors.initials: S
authors.lastname: Vedi
authors.forename: J E
authors.initials: JE
authors.lastname: Compston
authors.forename: J N
authors.initials: JN
authors.lastname: Beresford
authors.forename: A K
authors.initials: AK
authors.lastname: Bhalla
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D010044:Outpatient Clinics, Hospital; D011446:Prospective Studies; D012460:Sulfasalazine / Q000627:therapeutic use
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine; D008727:Methotrexate